Can oral orforglipron preserve weight loss after stopping tirzepatide or semaglutide?

In selected adults without diabetes, switching to orforglipron preserved more of their previous injectable-associated weight loss than switching to placebo over 52 weeks; continued injections were not compared.

Randomized trial · Nature Medicine 2026

Reference: Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;32(7):2679–2687. First published 13 May 2026. doi:10.1038/s41591-026-04386-7. PMID:42120723. https://pubmed.ncbi.nlm.nih.gov/42120723/

Chapters

0:00 Intro

0:38 The trial

3:31 My take

4:01 Outro

Read the structured trial summary at https://hormoneinsight.com/

AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.

Explore Hormone Insight:

Website: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en